ADIAL PHARMACEUTICALS, INC. (ADIL) Form 8-K — Aug 21, 2026
Adial Pharmaceuticals received a notice from Nasdaq dated August 18, 2026 stating that its stockholders' equity, as reported in its Form 10-Q for the period ended June 30, 2026, no longer satisfies the $2.5 million minimum required for continued listing on the Nasdaq Capital Market. The company also fails the alternative listing standards of $35 million in market value of listed securities or $500,000 in net income from continued operations. The notice has no immediate effect on the company's listing or trading.
Key figures
- Max extension days
- 180
- Deficiency notice date
- August 18, 2026
- Compliance plan deadline
- October 2, 2026
- Alternative standard net income usd
- 500000
- Alternative standard market value usd
- 35000000
- Minimum stockholders equity requirement usd
- 2500000
Price after filing
Close on the filing date to close N calendar days later (from $6.21). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.